These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27020403)

  • 41. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
    Brembilla NC; Chizzolini C
    Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced non-switched memory B cell subsets cause imbalance in B cell repertoire in systemic sclerosis.
    Simon D; Balogh P; Bognár A; Kellermayer Z; Engelmann P; Németh P; Farkas N; Minier T; Lóránd V; Czirják L; Berki T
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):30-36. PubMed ID: 27056741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autoimmunity in systemic sclerosis: current concepts.
    Boin F; Rosen A
    Curr Rheumatol Rep; 2007 May; 9(2):165-72. PubMed ID: 17502048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of B-Cell in the Pathogenesis of Systemic Sclerosis.
    Thoreau B; Chaigne B; Mouthon L
    Front Immunol; 2022; 13():933468. PubMed ID: 35903091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytokines in the immunopathology of systemic sclerosis.
    Raja J; Denton CP
    Semin Immunopathol; 2015 Sep; 37(5):543-57. PubMed ID: 26152640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.
    Matsushita T; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    Rheumatology (Oxford); 2016 Feb; 55(2):263-7. PubMed ID: 26350483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunologic aspects of scleroderma.
    White B
    Curr Opin Rheumatol; 1995 Nov; 7(6):541-5. PubMed ID: 8579976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
    Fuschiotti P; Medsger TA; Morel PA
    Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse.
    Saito E; Fujimoto M; Hasegawa M; Komura K; Hamaguchi Y; Kaburagi Y; Nagaoka T; Takehara K; Tedder TF; Sato S
    J Clin Invest; 2002 Jun; 109(11):1453-62. PubMed ID: 12045259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis.
    Taher TE; Ong VH; Bystrom J; Hillion S; Simon Q; Denton CP; Pers JO; Abraham DJ; Mageed RA
    Arthritis Rheumatol; 2018 Mar; 70(3):450-461. PubMed ID: 29193892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunopathogenesis of systemic sclerosis.
    White B
    Rheum Dis Clin North Am; 1996 Nov; 22(4):695-708. PubMed ID: 8923591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review.
    Campitiello R; Soldano S; Gotelli E; Hysa E; Montagna P; Casabella A; Paolino S; Pizzorni C; Sulli A; Smith V; Cutolo M
    Autoimmun Rev; 2024 Oct; 23(10):103637. PubMed ID: 39255852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.
    Tsuchiya N; Kuroki K; Fujimoto M; Murakami Y; Tedder TF; Tokunaga K; Takehara K; Sato S
    Arthritis Rheum; 2004 Dec; 50(12):4002-7. PubMed ID: 15593213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New insights into CD4(+) T cell abnormalities in systemic sclerosis.
    Liu M; Wu W; Sun X; Yang J; Xu J; Fu W; Li M
    Cytokine Growth Factor Rev; 2016 Apr; 28():31-6. PubMed ID: 26724976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of the acquired immune response in systemic sclerosis.
    Chizzolini C; Boin F
    Semin Immunopathol; 2015 Sep; 37(5):519-28. PubMed ID: 26152639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of IL-13 in systemic sclerosis.
    Fuschiotti P
    Cytokine; 2011 Dec; 56(3):544-9. PubMed ID: 21920770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
    Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.